P
Patrapim Sunpaweravong
Researcher at Prince of Songkla University
Publications - 41
Citations - 8499
Patrapim Sunpaweravong is an academic researcher from Prince of Songkla University. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 11, co-authored 32 publications receiving 7368 citations. Previous affiliations of Patrapim Sunpaweravong include University of Manitoba.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun,Lin Shen,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean-Philippe Metges,Zhigang Li,Sung Bae Kim,Byoung Chul Cho,Wasat Mansoor,Shau-Hsuan Li,Patrapim Sunpaweravong,Maria Alsina Maqueda,Eray Goekkurt,Hiroki Hara,Luis Carlos Moreira Antunes,Christos Fountzilas,Akihito Tsuji,Victor Castro Oliden,Qi Liu,Sukrut Shah,Pooja Bhagia,Ken Kato,Keynote Investigators +25 more
TL;DR: In this paper, the authors compared pembrolizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced oesophageal cancer and Siewert type 1 gastro-oesophagesphageal junction cancer.
Journal ArticleDOI
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Ronald B. Natale,Sumitra Thongprasert,F. Anthony Greco,Michael Thomas,Chun-Ming Tsai,Patrapim Sunpaweravong,D. R. Ferry,Clive Mulatero,Robert C. Whorf,Joyce Thompson,Fabrice Barlesi,Peter Langmuir,Sven Gogov,Jacqui Rowbottom,Glenwood D. Goss +14 more
TL;DR: In patients with previously treated advanced NSCLC, vandetanib showed antitumor activity but did not demonstrate an efficacy advantage compared with erlotinib, and both agents showed equivalent PFS and overall survival in a preplanned noninferiority analysis.
Journal ArticleDOI
LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Kyoko Kato,J-M. Sun,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,J.-P. Metges,Zhigang Li,S-B. Kim,B.C. Chul Cho,Wasat Mansoor,S-H. Li,Patrapim Sunpaweravong,M.A. Maqueda,Eray Goekkurt,Qi Liu,Sukrut Shah,Pooja Bhagia,Liang Shen +19 more
TL;DR: A large number of the patients treated at the Dana Farber Cancer Institute had no known prior history of Oncology or Hematology/Solid Tumor Disease, so it is likely that these patients did not have any prior indications of oncology problems.
Journal ArticleDOI
Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
Ronald B. Natale,Sumitra Thongprasert,F. A. Greco,Michael Thomas,Chun-Ming Tsai,Patrapim Sunpaweravong,David Ferry,Peter Langmuir,Jacqui Rowbottom,Glenwood D. Goss +9 more
TL;DR: The study did not meet its primary objective of demonstrating PFS prolongation with vandetanib vs erlotinib in patients with previously treated advanced NSCLC but showed equivalent efficacy for PFS and OS in a preplanned non-inferiority analysis.